trial

Stratification and Treatment in Early Psychosis Study - PROMOTE

NCTId NCT07434973
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Not Yet Recruiting
Enrollment 586 (estimated)
Sponsored by University of Oxford
Primary completion 2029-12-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Not Yet Recruiting
Enrollment
586 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2026-05-01
Primary completion
2029-12-01
Eligibility
ALL · 12 Years · 35 Years

Interventions & indications

Drugs
Cannabidiol

Sponsors

University of OxfordLead Sponsor
Wellcome TrustCollaborator
Jazz PharmaceuticalsCollaborator

Investigators

1
Philip McGuire, MD, PhD, ProfPrincipal Investigator

Sites

19 total
Vienna, AustriaMontreal, CanadaTurku, FinlandBerlin, GermanyCologne, GermanyLübeck, GermanyMünchen, GermanyAthens, GreeceBari, ItalyNaples, ItalyPavia, ItalyRoma, Italy

Linked catalysts

1
Stratification and Treatment in Early Psychosis Study - PROMOTE — primary completion2029-12-01

Facts & assertions

4 sourced
Enrollment
586
Phase
PHASE3
Primary Completion Date
2029-12-01
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Cannabidiol
drug
lead_sponsor
University of Oxford
company
collaborator
Wellcome Trust
company
Jazz Pharmaceuticals
company
indication
Clinical High Risk for Psychosis
indication
Clinical High Risk for Developing Psychosis
indication
Clinical High Risk for Psychosis (CHR)
indication
investigator
Philip McGuire, MD, PhD, Prof
person